Cosibelimab FDA Approval Status
FDA Approved: No
Generic name: cosibelimab
Company: Checkpoint Therapeutics, Inc.
Treatment for: Squamous Cell Carcinoma
Cosibelimab is an anti-PD-L1 antibody in development for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.
- Cutaneous squamous cell carcinoma is a type of skin cancer that can cause significant functional morbidities and cosmetic deformities, and can develop into a potentially life-threatening disease.
- Cosibelimab is a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 (PD-1) and B7.1 receptors. Cosibelimab works to treat cutaneous squamous cell carcinoma by removing the suppressive effects of PD-L1 on anti-tumor CD8+ T-cells to restore the cytotoxic T cell response.
Development timeline for cosibelimab
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.